Small Pharma Management
Management criteria checks 0/4
Small Pharma's CEO is George Tziras, appointed in Jul 2022, has a tenure of 1.25 years. directly owns 1.53% of the company’s shares, worth €527.98K. The average tenure of the management team and the board of directors is 1.3 years and 2.5 years respectively.
Key information
George Tziras
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 1.5% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2023 | n/a | n/a | -CA$19m |
| May 31 2023 | n/a | n/a | -CA$23m |
| Feb 28 2023 | n/a | n/a | -CA$23m |
| Nov 30 2022 | n/a | n/a | -CA$25m |
| Aug 31 2022 | n/a | n/a | -CA$23m |
| May 31 2022 | n/a | n/a | -CA$20m |
| Feb 28 2022 | CA$403k | CA$337k | -CA$22m |
| Nov 30 2021 | n/a | n/a | -CA$21m |
| Aug 31 2021 | n/a | n/a | -CA$18m |
| May 31 2021 | n/a | n/a | -CA$15m |
| Feb 28 2021 | CA$66k | CA$66k | -CA$7m |
Compensation vs Market: Insufficient data to establish whether George's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.
CEO
George Tziras
1.3yrs
Tenure
CA$402,552
Compensation
Mr. George Tziras served as Chief Business Officer of Small Pharma Inc. since January 2021 until July 2022 and also serves as its Non-Independent Director since April 29, 2021 and serves as its Chief Execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non-Independent Director | 1.3yrs | CA$402.55k | 1.53% € 528.0k | |
| Chief Financial Officer | 2.8yrs | CA$392.92k | 0.028% € 9.8k | |
| Chief Scientific & Medical Officer | 3.3yrs | CA$491.59k | 1.58% € 545.3k | |
| Chief Manufacturing & Development Officer & Director | 1.3yrs | CA$464.44k | 1.72% € 595.0k | |
| Chief Operating Officer | 1.3yrs | no data | 0% € 0 | |
| Head of Brand & Communications | 1.1yrs | no data | no data | |
| Head of Intellectual Property | 2.8yrs | no data | no data | |
| Corporate Secretary | no data | no data | no data | |
| Group Financial Controller | 1.3yrs | no data | no data | |
| Director of Development and Member of Scientific & Advisory Board | 7.4yrs | no data | no data |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Management: XC6's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non-Independent Director | 2.5yrs | CA$402.55k | 1.53% € 528.0k | |
| Chief Manufacturing & Development Officer & Director | 2.5yrs | CA$464.44k | 1.72% € 595.0k | |
| Director of Development and Member of Scientific & Advisory Board | 6.3yrs | no data | no data | |
| Non-Executive Independent Director | 1.9yrs | CA$21.43k | no data | |
| Independent Director | 2.5yrs | CA$62.98k | 0.030% € 10.3k | |
| Non-Executive Independent Chairman | 2.5yrs | CA$93.96k | 0.060% € 20.6k | |
| Member of Scientific & Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific & Advisory Board | 6.3yrs | no data | no data |
2.5yrs
Average Tenure
60yo
Average Age
Experienced Board: XC6's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/26 23:50 |
| End of Day Share Price | 2023/10/23 00:00 |
| Earnings | 2023/08/31 |
| Annual Earnings | 2023/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Small Pharma Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Elemer Piros | D. Boral Capital LLC. |
| Sepehr Manochehry | Eight Capital |